RecruitingPhase 2interventionalRules rewrite

Phase 2: ASY202 for Migraine

Q: Is NCT07646613 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07646613?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07646613?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a dummy treatment (placebo) (inactive treatment) at different times during the study.

Official registry: https://clinicaltrials.gov/study/NCT07646613 · Aspeya, Inc. · enrollment listed as 108

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are ASY202, or Placebo. The registry lists allocation as randomized. This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.

They plan to enroll about 108 people at 20 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

A Randomized, Double-blind, Placebo-controlled, Crossover, Multi-center Clinical Trial for the Evaluation of Efficacy, Safety, and Tolerability of ASY202 for the Acute Treatment of Migraine in Adult Patients

Interventions: ASY202, Placebo

Primary outcome (registry wording): Proportion of patients with freedom from headache pain at 2 hours post-dose

Who it is for (from inclusion criteria)

Ages 18 Years to 65 Years
Male or female, 18-65 years of age at Screening
body-mass index (BMI) between 18.5-35 kg/m² at Screening
Documented history of migraine (with or without aura) for ≥1 year, consistent with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
Female participants must be either:
of non-childbearing potential, or
of childbearing potential using protocol required contraception

Who the registry excludes

Diagnosis of headache conditions other than migraine
History or current diagnosis of coronary artery disease (CAD)
History of percutaneous coronary intervention, cardiac surgery, sepsis or vascular surgery
History or current diagnosis of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, or subarachnoid hemorrhage
Known allergic reactions, hypersensitivity, or contraindications to DHE, other ergot-derived products, or any other excipient in the formulation
Use of strong or moderate CYP3A4 inhibitors within 14 days (or 5 half-lives) or CYP3A4 inducers within 28 days (or 5 half-lives) prior to Randomization

Public study contact (from the registry)

Eken

+41 76 358 88 30

clinicaltrials@aspeya.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

20 listed

Arizona Research Center — Phoenix, Arizona (recruiting)
Synergy San Diego — Lemon Grove, California (recruiting)
Sunwise Clinical Research, Llc — Walnut Creek, California (recruiting)
New England Institute for Clinical Research — Stamford, Connecticut (recruiting)
Chase Medical Research — Waterbury, Connecticut (recruiting)
Clinical Neuroscineces Solutions - Orlando — Orlando, Florida (recruiting)
Clinical Neuroscineces Solutions — Orlando, Florida (recruiting)
Conquest Research — Atlanta, Georgia (recruiting)
Boston Clinical Trials — Roslindale, Massachusetts (recruiting)
Mass. Institute of Clinical Research — Westborough, Massachusetts (recruiting)
StudyMetrix Research — City of Saint Peters, Missouri (recruiting)
M3 Wake Research - Las Vegas Rainbow — Las Vegas, Nevada (recruiting)

Related recruiting trials in this snapshot

RecruitingPhase 3Birmingham, Alabama

Phase 3: testing Rimegepant/BHV3000 for Pediatric Migraine

This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.

NCT04649242 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3Scottsdale, Arizona

Phase 3: testing Rimegepant (PF-07899801) for Acute Treatment of Migraine

This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

NCT04743141 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3New Haven, Connecticut

Phase 3: testing Eptinezumab for Chronic Migraine in Children

To find out if eptinezumab is better than dummy treatment (placebo) (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

NCT04965675 · Official ClinicalTrials.gov record · H. Lundbeck A/S

FAQ about this NCT record

Is NCT07646613 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07646613?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07646613?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary